Srinivas Akkaraju - 24 May 2023 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Role: Director
Signature: /s/ Rocco Venezia, as attorney-in-fact
Issuer symbol: N/A
Transactions as of: 24 May 2023
Net transactions value: $0
Form type: 4
Filing time: 25 May 2023, 20:37:15 UTC
Previous filing: 16 Feb 2023
Next filing: 31 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICPT	Common Stock	Award	$0	+8,111	+21%	$0.000000	45,998	24 May 2023	Direct	F1
holding	ICPT	Common Stock						640,688	24 May 2023	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICPT	Option to Purchase Common Stock	Award	$0	+12,547		$0.000000	12,547	24 May 2023	Common Stock	12,547	$9.17	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.
F2	Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). The Reporting Person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. The Reporting Person disclaims beneficial ownership of these shares except to the extent of the Reporting Person's pecuniary interest therein.
F3	All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.